Skip to main content
Premium Trial:

Request an Annual Quote

BiOasis, UBC to Develop Alzheimer's PGx Test

NEW YORK (GenomeWeb News) – BiOasis Technologies and the University of British Columbia will collaborate to develop and test a biomarker assay for Alzheimer's disease, the company said today.

The goal of the collaboration is to develop and test concentration levels of the p97 protein in blood using an enzyme-linked immunosorbent assay test to diagnose Alzheimer's. The firms said that the "quick and accurate" test would help doctors diagnose the disease and monitor the effectiveness of therapeutics.

The one-year agreement between UBC and the Vancouver, BC-based company will attempt to correlate the presence of p97 in tissues with other markers of Alzheimer's disease, such as the presence of senile plaques, and to correlate that expression with other markers from human bioinformatic databases.

"Having a test, such as that afforded by the BiOasis product, could have significant benefit, because there are treatable diseases that can mimic Alzheimer's, and in addition, treatments currently available for Alzheimer's, although somewhat limited in their efficacy, have the greatest chances of benefiting a patient when started early," BiOasis Senior Medical Advisor Michael Shannon said in a statement.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.